These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 31511663)

  • 1. Targeting transcription factors in cancer - from undruggable to reality.
    Bushweller JH
    Nat Rev Cancer; 2019 Nov; 19(11):611-624. PubMed ID: 31511663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Undruggable Transcription Factors with PROTACs: Advances and Perspectives.
    Li Y; Song J; Zhou P; Zhou J; Xie S
    J Med Chem; 2022 Aug; 65(15):10183-10194. PubMed ID: 35881047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current strategies and progress for targeting the "undruggable" transcription factors.
    Zhuang JJ; Liu Q; Wu DL; Tie L
    Acta Pharmacol Sin; 2022 Oct; 43(10):2474-2481. PubMed ID: 35132191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
    González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
    Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ubiquitination and the Ubiquitin-Proteasome System as regulators of transcription and transcription factors in epithelial mesenchymal transition of cancer.
    Voutsadakis IA
    Tumour Biol; 2012 Aug; 33(4):897-910. PubMed ID: 22399444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting transcription factors by small compounds--Current strategies and future implications.
    Hagenbuchner J; Ausserlechner MJ
    Biochem Pharmacol; 2016 May; 107():1-13. PubMed ID: 26686579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The E3 ubiquitin ligase thyroid hormone receptor-interacting protein 12 targets pancreas transcription factor 1a for proteasomal degradation.
    Hanoun N; Fritsch S; Gayet O; Gigoux V; Cordelier P; Dusetti N; Torrisani J; Dufresne M
    J Biol Chem; 2014 Dec; 289(51):35593-604. PubMed ID: 25355311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1.
    Rao V; Guan B; Mutton LN; Bieberich CJ
    J Biol Chem; 2012 Oct; 287(43):36331-40. PubMed ID: 22910912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis.
    Zhang F; Virshup DM; Cheong JK
    Oncogene; 2018 Jan; 37(3):363-376. PubMed ID: 28945225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
    Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers.
    Illendula A; Gilmour J; Grembecka J; Tirumala VSS; Boulton A; Kuntimaddi A; Schmidt C; Wang L; Pulikkan JA; Zong H; Parlak M; Kuscu C; Pickin A; Zhou Y; Gao Y; Mishra L; Adli M; Castilla LH; Rajewski RA; Janes KA; Guzman ML; Bonifer C; Bushweller JH
    EBioMedicine; 2016 Jun; 8():117-131. PubMed ID: 27428424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.
    Zhao D; Lu X; Wang G; Lan Z; Liao W; Li J; Liang X; Chen JR; Shah S; Shang X; Tang M; Deng P; Dey P; Chakravarti D; Chen P; Spring DJ; Navone NM; Troncoso P; Zhang J; Wang YA; DePinho RA
    Nature; 2017 Feb; 542(7642):484-488. PubMed ID: 28166537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Studies of PROTACs in Hematological Malignancies.
    Fuchs O; Bokorova R
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NPDC-1, a novel regulator of neuronal proliferation, is degraded by the ubiquitin/proteasome system through a PEST degradation motif.
    Spencer ML; Theodosiou M; Noonan DJ
    J Biol Chem; 2004 Aug; 279(35):37069-78. PubMed ID: 15229225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation.
    Lin R; Heylbroeck C; Pitha PM; Hiscott J
    Mol Cell Biol; 1998 May; 18(5):2986-96. PubMed ID: 9566918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of the alpha-subunit of the eukaryotic initiation factor-2 (eIF2alpha) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition.
    Jiang HY; Wek RC
    J Biol Chem; 2005 Apr; 280(14):14189-202. PubMed ID: 15684420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6.
    Kerres N; Steurer S; Schlager S; Bader G; Berger H; Caligiuri M; Dank C; Engen JR; Ettmayer P; Fischerauer B; Flotzinger G; Gerlach D; Gerstberger T; Gmaschitz T; Greb P; Han B; Heyes E; Iacob RE; Kessler D; Kölle H; Lamarre L; Lancia DR; Lucas S; Mayer M; Mayr K; Mischerikow N; Mück K; Peinsipp C; Petermann O; Reiser U; Rudolph D; Rumpel K; Salomon C; Scharn D; Schnitzer R; Schrenk A; Schweifer N; Thompson D; Traxler E; Varecka R; Voss T; Weiss-Puxbaum A; Winkler S; Zheng X; Zoephel A; Kraut N; McConnell D; Pearson M; Koegl M
    Cell Rep; 2017 Sep; 20(12):2860-2875. PubMed ID: 28930682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.